க்யாத்ரிந் ஃப்லிந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from க்யாத்ரிந் ஃப்லிந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In க்யாத்ரிந் ஃப்லிந் Today - Breaking & Trending Today

Stopping CML Treatment Improves Quality of Life

December 15, 2020,
by NCI Staff
Drugs called TKIs are extremely effective in people with chronic myelogenous leukemia (CML), but can also cause side effects, including fatigue and depression.
Credit: iStock
For many people with chronic myelogenous leukemia (CML), the drug imatinib (Gleevec) changed a once-fatal blood cancer into a manageable disease and allowed them to live a nearly normal lifespan.
Until recently, imatinib and related drugs for CML, known as tyrosine kinase inhibitors (TKIs), had to be taken every day for life, and the drugs can cause fatigue, depression, disrupted sleep, diarrhea, and other side effects.
In 2018, based on results of two international studies, the Food and Drug Administration (FDA) approved an update to the recommended use of the TKI nilotinib (Tasigna) for CML. The update states that some people with CML who have been in remission for at least 3 years on nilotinib can safely stop taking the drug, although they m ....

United States , Ehab Atallah , H Jean Khoury , Brian Druker , Kathryn Flynn , Theodore Braun , Drug Administration , Moffitt Cancer Center , College Of Wisconsin , Research Institute , Oregon Health Science , Knight Cancer Institute , Kendra Sweet , Medical College , Oregon Health , Khoury Cure , ஒன்றுபட்டது மாநிலங்களில் , ஏஹாப் அதள்லாஹ் , ஏச் ஜீன் கௌரி , க்யாத்ரிந் ஃப்லிந் , தியோடர் மூளை , மாஃபிட் புற்றுநோய் மையம் , கல்லூரி ஆஃப் விஸ்கான்சின் , ஆராய்ச்சி நிறுவனம் , ஓரிகந் ஆரோக்கியம் அறிவியல் , நைட் புற்றுநோய் நிறுவனம் ,

Clinical Challenges: Discontinuing TKIs in Chronic Myeloid Leukemia

Treatment-free remission is now regarded as a primary aim of patients with long-term chronic myeloid leukemia (CML).
Starting with the approval of imatinib in 2001, the effectiveness of tyrosine kinase inhibitors (TKIs) has resulted in significant improvements in outcomes for CML patients, and with that success has come a focus on discontinuing treatment in patients when appropriate.
Results from trials such as the DADI (Dasatinib Discontinuation) and the STIM (Stop Imatinib) trials suggest this approach is feasible, and the National Comprehensive Cancer Network has modified its guidelines by incorporating TKI discontinuation in appropriately selected patients.
There are a number of factors that go into the decision to stop TKI treatments. They do come with side effects, as well as an accompanying impact on a patient s quality of life. These can include fatigue, nausea, sleep disturbance, and depression. Other issues include concerns about drug-drug interactions, finan ....

United States , Ehab Atallah , Kathryn Flynn , Kelly Schoenbeck , University Of California San Francisco , College Of Wisconsin , National Comprehensive Cancer Network , American Society Hematology , Dasatinib Discontinuation , Stop Imatinib , California San Francisco , Medical College , Life After Stopping , ஒன்றுபட்டது மாநிலங்களில் , ஏஹாப் அதள்லாஹ் , க்யாத்ரிந் ஃப்லிந் , கெல்லி ஸ்கொன்பெக் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா சான் பிரான்சிஸ்கோ , கல்லூரி ஆஃப் விஸ்கான்சின் , தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் , அமெரிக்கன் சமூகம் ஹீமாட்டாலஜி , கலிஃபோர்னியா சான் பிரான்சிஸ்கோ , மருத்துவ கல்லூரி ,